#NASH

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

Some 20% of those with NAFLD also showed signs of liver fibrosis.

Experts predict that more than a million people could die from liver cancer worldwide in 2040.

Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.

Another study found that children with fatty liver disease are at high risk for diabetes.

People with a tendency to be active later in the day may be at greater risk for severe NAFLD.

Non-alcoholic fatty liver disease is substantially more common among men compared with women.

Second- and third-generation individuals in Los Angeles had a 35% and 61% higher risk, respectively, than those born in Mexico.

Liver cancer is now less likely to be caused by hepatitis B or C, but more likely to be caused by fatty liver disease or alcohol.

Despite not cutting back on calories, people on the high fat diet lost more weight and had better blood sugar levels.

More than a third of hepatocellular carcinoma cases among Medicare recipients were due to fatty liver disease.

Higher daily alcohol consumption was linked to greater risk for MAFLD.

Noninvasive imaging may be the best way to screen for NAFLD in this population.

Abdominal obesity worsened the impact of air pollution on MAFLD development.

Over the next two decades, obesity-linked NASH will lead to more deaths and high cost in the United States.